International Multicenter Glaucoma Research

The review paper presents the results of large-scale international multicenter research of glaucoma. The research has a considerable impact on today’s understanding of strategies of glaucoma diagnosis and treatment. The conclusions made by the authors of this research are heavily cited in ophthalmological literature but its structure, vital for proper interpretation of research details and results, is often disregarded. Randomized clinical studies are extremely important for the selection of correct management of patients with glaucoma or ocular hypertension. The reviewed research showed, for the first time, that IOP reduction definitely slows the progression of glaucoma and reduces the probability that ocular hypertension develops into glaucoma. IOP reduction slows down the progression of glaucoma even if its level is conditionally normal, and the risk of progression is reduced drastically (by some estimates, this risk drops about 10 % per 1 mmHg of IOP reduction). It is noted that various surgical interventions (argon laser trabeculoplasty, trabeculectomy) increase the degree and duration of IOP compensation, but the risk of complications may be different for different operations. The research identifies the major risk factors of glaucoma progression (advanced age, increased IOP, optic disc hemorrhages) and of transition of ocular hypertension to glaucoma (increased IOP, age, lower central corneal thickness and optic disc hemorrhages). The progression rate has been found to depend on the intraocular pressure level as measured at the moment of the detection of the disease, and on the stage of the disease. Besides, the study suggests a differentiated approach to the choice of patient management tactics, including the choice of “wait-and-see” tactics under adequate monitoring of the key parameters of progression, especially of perimeter indices and the condition of the optic nerve. The results of randomized clinical studies permit to achieve a more targeted and effective glaucomatous therapy and to form an evidence-based management of patients in different clinical situations // Russian Ophthalmological Journal, 2016; 2: 96-101 . doi: 10.21516/2072-0076-2016-9-2-96-101 .

глаукома, офтальмогипертензия, внутриглазное давление, факторы риска, параметры прогрессирования, glaucoma, ocular hypertension, intraocular pressure, risk factors, progression markers

1. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. American Journal of Ophthalmology. 1998; 126 (4): 487-97.

2. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. American Journal of Ophthalmology. 1998; 126 (4): 498-505.

3. Anderson D.R., Drance S.M., Schulzer M. Collaborative Normal-Tension Glaucoma Study Group. Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma. American Journal of Ophthalmology. 2003; 136 (5): 820-9.

4. Anderson D.R., Drance S.M., Schulzer M. Collaborative Normal-Tension Glaucoma StudyGroup. Natural history of normal-tension glaucoma. Ophthalmology. 2001; 108 (2): 247-53.

5. Drance S., Anderson D.R., Schulzer M. Collaborative Normal-Tension Glaucoma StudyGroup. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. American Journal of Ophthalmology 2001; 131 (6): 699-708.

6. Leske M.C., Heijl A., Hyman L., Bengtsson B. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology. 1999; 106 (11): 2144-53.

7. Bengtsson B., Leske M.C., Hyman L., Heijl A. Early Manifest Glaucoma Trial Group. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007; 114 (2): 205-9.

8. Heijl A., Leske M.C., Bengtsson B., Bengtsson B., Hussein M. Early Manifest GlaucomaTrialGroup. Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmologica Scandinavica. 2003; 81 (3): 286-93.

9. Heijl A., Leske M.C., Bengtsson B., et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology. 2002; 120 (10): 1268-79.

10. Hyman L.G., Komaroff E., Heijl A., Bengtsson B., Leske M.C. Early Manifest GlaucomaTrial Group. Treatment and vision-related quality of life in the early manifest glaucoma trial. Ophthalmology. 2005; 112(9): 1505-13.

11. Leske M.C., Heijl A., Hussein M., et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Archives of Ophthalmology. 2003; 121(1): 48-56.

12. Leske M.C., Heijl A., Hyman L., et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007; 114(11): 1965-72.

13. Heijl A., Leske M.C., Hyman L., et al. Intraocular pressure reduction with a fixed treatment protocol in the Early Manifest Glaucoma Trial. Acta Ophthalmologica. 2011; 89 (8): 749-54.

14. Heijl A., Peters D., Leske M.C., Bengtsson B. Effects of argon laser trabeculoplasty in the Early Manifest Glaucoma Trial. American Journal of Ophthalmology. 2011; 152 (5): 842-8.

15. Hyman L., Heijl A., Leske M.C., Bengtsson B., Yang Z. Early Manifest Glaucoma Trial Group. Natural history of intraocular pressure in the early manifest glaucoma trial: A 6-year follow-up. Archives of Ophthalmology. 2010; 128(5): 601-7.

16. Heijl A., Bengtsson B., Hyman L., Leske M.C. Early Manifest Glaucoma Trial Group. Natural history of open-angle glaucoma. Ophthalmology. 2009; 116 (12): 2271-6.

17. Heijl A., Bengtsson B., Chauhan B.C., et al. A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. Ophthalmology. 2008; 115 (9): 1557-65.

18. Bengtsson B., Leske M.C., Yang Z., Heijl A., Group E. Disc hemorrhages and treatment in the early manifest glaucoma trial. Ophthalmology. 2008; 115(11): 2044-8.

19. Gordon M.O., Kass M.A. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Archives of Ophthalmology. 1999; 117 (5): 573-83.

20. Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of Ophthalmology. 2002; 120(6): 701-13; discussion: 829-30.

21. Kass M.A., Gordon M.O., Gao F., et al. Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Archives of Ophthalmology. 2010; 128 (3): 276-87.

22. Budenz D.L., Anderson D.R., Feuer W.J., et al. Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study. Ophthalmology. 2006; 113 (12): 2137-43.

23. Herman D.C., Gordon M.O., Beiser J.A., et al. Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study. American Journal of Ophthalmology. 2006; 142 (5): 800-10.

24. Bhorade A.M., Wilson B.S., Gordon M.O., et al. The utility of the monocular trial: data from the ocular hypertension treatment study. Ophthalmology. 2010; 117 (11): 2047-54.

25. Barnett E.M., Fantin A., Wilson B.S., Kass M.A., Gordon M.O. Ocular Hypertension Treatment Study Group. The incidence of retinal vein occlusion in the ocular hypertension treatment study. Ophthalmology. 2010; 117 (3): 484-8.

26. Miglior S., Zeyen T., Pfeiffer N., et al. The European glaucoma prevention study design and baseline description of the participants. Ophthalmology. 2002; 109 (9): 1612-21.

27. Miglior S., Zeyen T., Pfeiffer N., et al. Results of the European Glaucoma Prevention Study. Ophthalmology. 2005; 112 (3): 366-75.

28. Miglior S., Pfeiffer N., Torri V., et al. Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology. 2007; 114 (1): 3-9.

29. Musch D.C., Lichter P.R., Guire K.E., Standardi C.L. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999; 106(4): 653-62.

30. Lichter P.R., Musch D.C., Gillespie B.W., et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001; 108 (11): 1943-53.

31. Musch D.C., Gillespie B.W., Niziol L.M., Cashwell L.F., Lichter P.R. Collaborative Initial Glaucoma Treatment StudyGroup. Factors associated with intraocular pressure before and during 9 years of treatment in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2008; 115 (6): 927-33.

32. Musch D.C., Gillespie B.W., Niziol L.M., et al. Cataract extraction in the collaborative initial glaucoma treatment study: incidence, risk factors, and the effect of cataract progression and extraction on clinical and quality-of-life outcomes. Archives of ophthalmology. 2006; 124 (12): 1694-700.

33. Musch D.C., Gillespie B.W., Lichter P.R., et al. Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. Ophthalmology. 2009; 116 (2): 200-7.

34. Musch D.C., Gillespie B.W., Niziol L.M., et al. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2011; 118 (9): 1766-73.

35. Janz N.K., Wren P.A., Lichter P.R., et al. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology. 2001; 108 (11): 1954-65.

36. Parrish R.K., 2nd, Feuer W.J., Schiffman J.C., et al. Five-year follow-up optic disc findings of the Collaborative Initial Glaucoma Treatment Study. American Journal of Ophthalmology. 2009; 147 (4): 717-24 e1.

37. Ederer F., Gaasterland D.E., Sullivan E.K., Investigators A. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients. Controlled clinical trials. 1994; 15 (4): 299-325.

38. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. American Journal of Ophthalmology. 2000; 130 (4): 429-40.

39. The advanced glaucoma intervention study, 6: effect of cataract on visual field and visual acuity. The AGIS Investigators. Archives of Ophthalmology. 2000; 118 (12): 1639-52.

40. Ederer F., Gaasterland D.A., Dally L.G., et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results. Ophthalmology. 2004; 111 (4): 651-64.

41. AGIS Investigators A. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. American Journal of Ophthalmology. 2001; 132(3): 311-20.

42. Nouri-Mahdavi K., Hoffman D., Coleman A.L., et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004; 111 (9): 1627-35.

43. Caprioli J., Coleman A.L. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008; 115 (7): 1123-9 e3.

44. AGIS Investigators A. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. American Journal of Ophthalmology. 2002; 134 (4): 481-98.